Asian Market to See Increase
SINGAPORE, /PRNewswire-AsiaNet/ --
Oral Therapy in Type 2 Diabetes Therapeutics Market
Although currently Metformins and SFUs are most preferred medications, in the future, new products such as
DPP-4, GLP-1, DGAT are likely to be used by the physicians which thereby increasing the number of type 2
patients on oral antidiabetic drugs. The use of oral therapy is likely to increase while the use of insulin would
decline due to the earlier detection of the disease. Patients are more compliant to early control and the availability
of an increasing array of oral antidiabetics. The global prevalence of diabetics is also driving the development of
new therapies and is resulting in pharmaceuticals companies to increase efforts on novel agents and therapies
that treat diabetes.
Frost & Sullivan Research Analyst Sushma Rajan says, across most countries there is sufficient government
support provided to control this disease, thus, there are minimal market restraints. In South Korea however,
the government has lack of support on programs and public educations for diabetes as they tend to focus on
other major diseases such as cancer.
"If compared to Taiwan, the government has set up a program for diabetes medical treatment through patient
self help groups, pay-for-performance scheme and also adopted various channels for diabetes education," Rajan
further elaborates.
It is crucial for both government and pharmaceutical companies to create awareness about the disease and
enhance treatment acceptance by providing education programs. Through the increase in awareness, better
diagnosis and government initiatives, the number of patients diagnosed and treated will increase. This will then
open up a larger pool of patients for treatment than at present.
Across the three countries namely, Australia, South Korea and Taiwan, in order to increase the usage of drugs,
manufactures need to bring their drugs under the reimbursement scheme so that drugs become affordable and
available to a larger patient pool.
Opportunities exist for insulin manufactures in all Australia, South Korea and Taiwan to work with the Ministry
of Health for diabetes awareness, to encourage early detection and prevention of diabetes and educate physician
through seminars/conferences.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in
class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the
CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation,
evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of
experience in partnering with Global 1000 companies, emerging businesses and the investment community from
Contact:
Emmie Kaur
Corporate Communications - Healthcare, Asia Pacific
DID: +603 6204 5913
Email: emmie.kaur@frost.com
Jasminder Kaur
Corporate Communications - Healthcare, Asia Pacific
DID: +65 6890 0937
Email: jkaur@frost.com
SOURCE: Frost & Sullivan
NEWS 
